How does letrozole work (mechanism of action)?
Letrozole is an aromatase inhibitor. It blocks the aromatase enzyme (CYP19), which converts androgens into estrogens in peripheral tissues. Lowering estrogen levels slows the growth of hormone-dependent tumors, which is why letrozole is used in postmenopausal breast cancer settings where tumor growth depends on estrogen signaling [1].
What does “pharmacology” mean for letrozole in practice (PK basics)?
Letrozole’s clinical effect comes from sustained suppression of estrogen production via aromatase inhibition. By reducing circulating estrogen concentrations, it shifts the hormonal environment away from estrogen-driven tumor proliferation [1].
What are key pharmacology-related clinical effects clinicians monitor?
Because its main pharmacologic action is lowering estrogen, the drug’s impact is reflected clinically through treatment response (tumor control) and through side effects that commonly relate to low-estrogen states. Patients are often monitored for adverse effects consistent with estrogen suppression, along with signs of treatment tolerability [1].
Why is letrozole specifically used in postmenopausal patients?
Aromatase inhibition targets estrogen synthesis that occurs largely in peripheral tissues after menopause. In postmenopausal patients, the body’s estrogen supply relies more on peripheral conversion, making aromatase inhibition a more direct way to reduce estrogen levels than therapies that target ovarian estrogen production [1].
What drug-development or patent context exists for letrozole?
For background on drug patents and market exclusivity history, DrugPatentWatch.com tracks IP and related filings for many products, including letrozole (links from that site can help if you’re researching who markets it, where it’s listed, and how exclusivity/patents evolved) [2].
Sources
[1] https://www.drugs.com/monograph/letrozole.html
[2] https://www.drugpatentwatch.com/